

CURRICULUM VITAE

Name: Cara C. Wilson, M.D.

Home: 1780 Larkspur Drive, Golden, Colorado 80401

Work: University of Colorado at Denver
Medicine - Infectious Diseases, Mail Stop #B168
Building P15 Research 2, Room # 11011
12700 E. 19th Ave. (P.O. Box 6511)
Aurora, CO 80045

Date of Birth: November 17, 1961

Place of Birth: Spartanburg, South Carolina

Education:

1980-84	B.S. Duke University
1984-88	M.D. University of Virginia School of Medicine

Postdoctoral Training:

1988-89	Intern in Internal Medicine, Johns Hopkins Hospital, Baltimore
1989-91	Resident in Internal Medicine, Johns Hopkins Hospital, Baltimore
1991-92	Clinical Fellow, Infectious Diseases Division, Massachusetts General Hospital, Boston, MA
1992-95	Research Fellow, Infectious Diseases Divisions, Massachusetts General Hospital, Boston, MA

Licensure and Certification:

1991	Massachusetts License of Registration (inactive)
1991	Diplomate, American Board of Internal Medicine
1994	Diplomate, American Board of Internal Medicine, Infectious Disease Subspecialty, Recertification 2008
1995	Pennsylvania License Registration (inactive)
1998	Colorado License Registration (active)

Academic Appointments:

1991-95	Research Fellow in Medicine, Harvard University
1995	Instructor in Medicine, Harvard Medical School
1995-97	Research Associate in Medicine, University of Pittsburgh School of Medicine
1997	Instructor in Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine (Primary)
1997	Research Associate, Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health (Secondary)
1997-98	Assistant Professor of Medicine, University of Pittsburgh School of Medicine
1998-03	Assistant Professor of Medicine, jointly appointed in Divisions of Infectious Diseases and Clinical Immunology, University of Colorado School of Medicine
2000-03	Assistant Professor, Department of Immunology, University of Colorado

2003-	School of Medicine and National Jewish Medical Research Center Associate Professor of Medicine and Immunology, University of Colorado School of Medicine and National Jewish Medical Research Center
7/2011-	Professor of Medicine with tenure, University of Colorado at Denver and Health Sciences Center

Hospital Appointments:

1991-95	Clinical Fellow, Massachusetts General Hospital
1995-98	Staff Physician, University of Pittsburgh Medical Center
1998-	Staff Physician, University of Colorado Health Sciences Center

Awards and Honors:

1981-83	Dean's List and Class Honors, Duke University
1983	Nominated for Junior Marshall
1983	Phi Beta Kappa, Early Selection, Duke University
1984	Summa cum laude, Duke University
1987	Junior Selection to Alpha Omega Alpha, University of Virginia
1988	Janet M. Glasgow Memorial Award of the American Medical Women's Association
1988	Scholarship Award, Graduating Class of 1988, University of Virginia School of Medicine
1994-96	Infectious Diseases Society of America Roche Laboratories Post Doctoral Award in Virology
1997	Infectious Diseases Society of America Ortho Pharmaceutical Corporation and McNeil Pharmaceutical Young Investigator Award in Infectious Diseases

Memberships, Offices, Committee Assignments in Professional Societies:

1987-88	President of Alpha Chapter, AOA
1989-91	American Medical Association
1992-	American College of Physicians
1992-	Infectious Diseases Society of America
1993-	American Association for the Advancement of Science
1996-97	Member of the Pittsburgh Cancer Institute, Biologic Therapeutics Program
1997-98	Primary Faculty of SHARP Program (Support for HIV/AIDS Research at Pitt)
1997-98	Chair, Seminar Committee, Infectious Diseases and Microbiology Division (Univ. of Pittsburgh)
1998-	Member of the Colorado AIDS Clinical Trials Group (ACTG)
2000-	American Association of Immunologists
2000-	Member of the Therapeutic Immunology Subcommittee (TISC) and the Therapeutic Vaccine Working Group of the ACTG
2001	Committee for Ionizing Radiation, UCHSC
2001	Medical Scientist Training Program (MSTP) Internal Review Committee
2001	Member of the Scientific Advisory Committee of the Adult General Clinical Research Center (GCRC) at UCHSC
2002-	Member of the Immunology Graduate Program and Retreat Committees
2001-03	Member of the Immunology Research Agenda Committee (IRAC) of the ACTG
2003	Member of MSTP Admissions Committee
2003-05	External advisor for the University of Pittsburgh Program Project grant entitled "Dendritic Cell-Based Immunotherapy for HIV Infection."
2004-06	Vice Chair of the Translational Research and Drug Development

	Committee of the ACTG
2004-	Advisory Board Member, Zimbabwe AIDS Treatment Assistance (ZATA) Project
2006	Co-Director of the Developmental Core, Colorado Center for AIDS Research
2007-09	Chair of the Translational Research and Drug Development Committee of the ACTG
2007-12	Invited to serve on the NIH NIAID AIDS Research Review Committee (RCC) as standing member
2007-	Member of the advisory board for the UCHSC K12 Clinical Oncology Research Program.
2007-10	Director of the Clinical Investigation Core, Colorado Center for AIDS Research
2007	Member of the Infectious Diseases Division Executive Committee, UCHSC
2008	Organizing committee member for the Translational Immunology Seminar series (joint UCDHSC-NJMRC)
2009-	Member of the Board of Directors, Mucosal and Vaccine Research Center Colorado (MAVRC)
2009	Member of the Anal Health Working Group, Infectious Diseases Group Practice, UC Denver
2009-	Vice chair of the Immune Activation Focus Group of the ACTG
2009-	Member, Mucosal Immunology Society
2010	Steering Committee Member, 2010 Colorado Vaccine Summit
2010-	Member, Dept. of Immunology Steering Committee on Graduate Training
2010-13	Member of the Medical Scientist Training Program Admissions Committee
2010-	Member, American Association of Immunologists
2010-11	Member, Institutional Biosafety Committee, UC Denver
2010-11	Member, International Society for Dendritic Cell and Vaccine Science
2011-	Member of Inflammation and End Organ Disease Transformative Science Group (ITSG) of the ACTG
2011	Member of the Department of Medicine Mentoring Task Force
2011-	Co-chair of the Institutional Biosafety Committee, UC Denver
2011-	Member of PhD Shadowing Program Committee, Dept. of Immunology
2012-	Member of HIV Eradication (Cure) TSG of the ACTG and Invited to serve on Therapeutic Vaccination Focus Group of the Cure TSG
2012 -	Member of the Steering Committee for the HIV Training Grant, ID division
2013-	Member, Infectious Diseases Division Incentive Plan Committee
2013 -	Member, University Scientific Ethics Committee
2013-14	Leadership for Innovative Team Science (LITeS) Program, Colorado Clinical and Translational Sciences Institute (CCTSI)
2014 -	Member of the Council of Graduate Educators, University of Colorado
2014 -	Director, pre-K mentoring program; Co-director KL2 program (CCTSI)
2015-	Vice Chair for Faculty Advancement, Department of Medicine, University of Colorado
2015 -	Selected to the NIAID/NIH Advisory Council
2016-	Committee Member for Doris Duke Fund to Retain Clinical Scholars

Teaching and Mentoring Activities:

1988	Clinical Skills Tutorials as Service of AOA
1996-98	Facilitator for Problem-Based Learning Courses, <i>Host Defenses</i> and <i>Molecular Pathogenesis of Infectious Diseases</i> , University of Pittsburgh School of Medicine
1997	Primary Faculty Lecturer for IDM 2003 course: Host Response to Microbial Infections, Graduate School of Public Health

1997 Instructor for *Integrated Case Studies*, University of Pittsburgh School of Medicine

1998-present Graduate Thesis/Post-graduate Research Committee Member for:

- Yue Chen, Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, PhD received 1999.
- Winston Chamberlain, MSTP student, UCHSC, PhD received 2000.
- Larissa Thackray, Department of Microbiology, UCHSC, initiated 2001.
- Carl Gelhaus, Department of Immunology, UCHSC initiated 2001.
- Jeff Colbert, Department of Immunology, UCHSC/NJMRC initiated 2002.
- Christine Meadows, UCHSC Dept. of Microbiology, initiated 2002.
- Lindsay Edwards, MSTP student, Dept. of Immunology, 2007 to 2011.
- Elisabeth Bowers, Department of Microbiology, 2007 to 2013.
- Richard Sullivan, Department of Immunology, 2009 to 2012.
- Kristine Erlandson, fellow in Infectious Diseases, HIV training grant, 2009 to 2011.
- Amy Stone, Department of Immunology, 2010 to 2013.
- Claire Gustafson, Department of Immunology, 2011 to 14.
- Kristin Shotts, graduate student in Department of Immunology, clinical preceptor and committee member, 2013 – present.
- Mastoreh Chamanian and Brodie Miles (postdoctoral fellows), HIV training grant committee member, 2013-14.
- Kristine Erlandson (faculty in I.D. division), Clinical Sciences Master's program committee member, 2013-15.
- Mike Harper, MSTP student (Immunology), 2014 – 2015.
- Eric Cross, MSTP student (Dept. of Immunology), clinical preceptor for Foundations of Doctoring and thesis committee member, 2014- present.
- Kristi Kuhn, M.D. (faculty in GI division), scientific mentoring committee, 2015 – present
- Michael Kriss, M.D. (faculty in GI division), scientific mentoring committee, GI T32 mentoring committee, 2015-16.
- William Crisler, graduate student in Immunology, thesis committee member 2016 to present.

1999-present Comprehensive Exam Committee Member for:

- Sean Bennett, MSTP student, UCHSC, exam in 1999.
- Dalya Rosner, UCHSC Dept. of Immunology graduate student, exam in 2000.
- Joe Delli, UCHSC Dept. of Immunology graduate student, exam in 2001.
- Christina Meadows, UCHSC Dept. of Microbiology, exam 2001, re-exam 2002.
- Elisabeth Bowers, UCHSC Dept. of Microbiology, exam 12/2006.
- *On comprehensive exam committee for Immunology, May 2013

1999-present Primary Research Mentor for:

- Andrew Stubbs, postdoctoral fellow with PhD in molecular genetics from the Liverpool School of Tropical Medicine, UK, 1999 to 2002, Project title: "Recombinant yeast-based vaccines for HIV-1".
- Brent Palmer, previous postdoctoral fellow with PhD in immunology from Colorado State University, 1999 to 2005, Project title: "Mechanisms of HIV-specific T helper cell dysfunction".

- Michelle Barron, previous M.D. fellow in Infectious Diseases, Department of Medicine, UCHSC, 2000 to 2003, Project title: "Role of dendritic cells in T cell reconstitution following highly active antiretroviral therapy in HIV infection".
- Eli Boritz, completed combined M.D./Ph.D. degree at UC Denver. Performed his PhD thesis work in my lab from September 2000-2004, Project title: "Breadth and specificity of the clonal HIV-specific T helper cell response".
- Samuel Pan, previous UCHSC Dept of Immunology Ph.D. candidate. Thesis work performed 2001-2002, Project title: "Antigen processing of yeast-expressed antigens".
- John Koepppe, previous M.D. fellow in Infectious Diseases. Research project from July, 2002-2004, Project title: "Immune escape from CD4 detection by HIV."
- Katie Robertson, previous M.D. fellow in Infectious Diseases. Research initiated July 2004 and completed 2005, Project title: "HIV-associated blood dendritic cell defects".
- Phil Kuo, previous M.D. fellow in Allergy and Clinical Immunology. Research initiated in July 2005 with projected completion 2006. Project title: "Immunologic control of viral setpoint in drug resistant HIV infection".
- Rawleigh Howe, previous M.D. fellow in Infectious Diseases, had also received a PhD in Immunology from Washington University, research from 2006-2008, Project title: "Role of HIV-specific CD4+CD8+ co-expressing T cells in HIV-1 pathogenesis".
- Stephanie Dillon – current Assistant Research professor, received her PhD in Immunology in New Zealand, postdoctoral training with Dr. Bali Pulendran at Emory University, research here initiated 12/2005, promoted to instructor in 2007 and to Assit. Research Professor in 2014, Project title: "Interactions between HIV-1 and human blood dendritic cells".
- Jennifer Manuzak –Ph.D. candidate in Dept. of Immunology, thesis project started 7/2009, project title: "Impact of HIV-1 on Intestinal Dendritic Cell Responses to Commensal Gut Flora." PhD obtained in June 2013.
- Kevin Rufner, M.D. –fellow in the Division of Gastroenterology, research project 7/2010-7/2012, project title: "Immunologic Function and Interactions of Human Intestinal Epithelial Cells and Lamina Propria Dendritic Cells in Human Immunodeficiency Virus Infection."
- Uriel Alejandro López Lemus – previously a graduate student obtaining his Ph.D. at the Universidad De Colima, Colima, Mexico. He performed research in my laboratory from January through March of 2011 as part of the Exchange Visitor Program. The title of his project was "Commensal Bacteria-reactive T Lymphocytes and Natural Killer Cell Responses in HIV-1 Infection."
- Amanda Leone –a postdoctoral fellow in my laboratory from 2012-2014,

her research project entitled “Mechanisms of Depletion of Intestinal CD4 Cells” was supported by the HIV Training grant in the I.D. Division.

-Jon Kibbie – MD/PhD candidate in MSTP and Immunology programs, 2015 to present. Research project entitled “Immunomodulatory effects of the short chain fatty acid butyrate during HIV-1 infection in the gut.”

-Jay Lieu – M.D./PhD fellow in the Division of Infectious Diseases, 2015 to present, project entitled “Investigations of the effect of aging and HIV on the gut microbiome.”

- Thien Le – medical student at UCD, am serving as advisor for his Mentored Scholarly Activity project, 2015 to present.

- Alyson Yoder – postdoctoral fellow with PhD in Molecular Virology, 2015 to present, project entitled “Gene signatures of HIV-infected and exposed gut CD4 T cells”.

2000-present Instructor for *Core Immunology course (Immunology 7662)* and *Special Topics in Immunology Course* for graduate students in the Department of Immunology, NJMRC/UCHSC

2002-present Instructor for *Microbiology 6000* and *Pathophysiology of Infectious Diseases* courses for medical students

Clinical Activities:

1997-98 Attending, inpatient and outpatient Infectious Diseases consult service, University of Pittsburgh Medical Center
6/2002 Attending, inpatient General Medicine service, UCHSC
1998-present Attending, inpatient Infectious Diseases consult service, UCHSC
2001-present Attending, Infectious Diseases Group Practice outpatient clinic, UCHSC
2009 Member of the Anal Health Working Group to develop an Anal Cancer Screening program for the Infectious Disease Group Practice clinic.
2012- present Clinical mentor for MSTP (foundations of doctoring) and graduate students in CCTSI predoctoral fellowship programs – including Jennifer Manuzak, Kristin Shotts, and Eric Cross.

Clinical Research Activities:

2001 Randomized Phase I/II Evaluation of Immunization With Highly Conserved HIV-1 Derived Peptides and Influenza Matrix Peptide in HIV-1-infected Subjects on Highly Active Antiretroviral Therapy (HAART) Using Autologous Dendritic Cells Derived from Adherent Monocytic Precursors. Role: Co-principal investigator. Site: University of Pittsburgh Medical Center. Funding: NIH.

2002 A Single Center Phase I Safety and Immunogenicity Study of the Epimmune HIV-1 CTL Epitope-based DNA Vaccine (EP-HIV-1090) for Immunotherapy of HIV-1-infected Individuals Receiving Highly Active Antiretroviral Therapy (HAART). Role: Co-Chair. Site: UCHSC. Funding: NIH.

2002 A Phase I/II Study to Evaluate the Safety and Immunogenicity of the Subcutaneous Administration of MVA-mBN32 Epitope-based HIV-1 Vaccine in HIV-1-infected Subjects.

Role: Principal Investigator. Funding: ACTG/NIH

2002-present Site PI for therapeutic vaccination studies (Merck, Wyeth, Pharmexa-Epimmune), novel antiretroviral drug studies (Panacos, Progenics), and completed ACTG studies (A5232, A5212, 5248, 5256).

Ongoing/Developing/Completed Multi-center Clinical Protocols:

ACTG 5262: *A Pilot Efficacy and Safety Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects.* Completed. Role: Protocol Immunologist.

ACTG 5258: *A Phase II, Double Blind, Randomized, Exploratory Study of Chloroquine for Reducing HIV-Associated Immune Activation.* Completed. Role: Co-investigator.

ACTG 5286: *A Pilot Study of Rifaximin as a Modulator of Gut Microbial Translocation and Systemic Immune Activation in HIV-Infected Individuals with Incomplete CD4+ T-cell Recovery on Antiretroviral Therapy.* Completed. Role: Co-Chair.

ACTG 5281: *A Phase I Randomized, Partially Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of a Cytokine Enhanced HIV-1 Multi-Antigen pDNA Vaccine Delivered Intramuscularly (IM) or IM in Combination with In Vivo Electroporation (IM/EP) in HIV-1 Infected Adults Receiving HAART.* Completed. Role: Co-Vice chair.

ACTG 5303: *An Exploratory Randomized Trial to Determine the Bone, Renal, Central Nervous System and Immunological Effects of a Tenofovir-sparing, Maraviroc-containing Antiretroviral Regimen in Treatment-Naïve Patients infected with R5-tropic HIV-1.* Completed. Role: Co-investigator.

ACTG 5296: *Sevelamer for Reducing Endotoxemia and Immune Activation: A Proof of Concept Study.* Completed. Role: Co-vice chair.

ACTG DACS 266: *Changes in CD28 expression on CD4 and CD8 cells after antiretroviral treatment initiation.* Analysis completed, manuscript published. Role: Co-investigator.

HVTN 505: *Phase 2, randomized, placebo-controlled trial to evaluate the safety and effect on post-HIV acquisition viremia of a multiclade HIV-1 DNA plasmid vaccine followed by a multiclade HIV-1 recombinant adenoviral vector vaccine in HIV-uninfected, adenovirus type 5 neutralizing antibody negative, circumcised men and transgender women, who have sex with men.* Open to enrollment. Role: Site Co-investigator.

ACTG NWCS 329: *Activation, Inflammation and Non-HIV Related Events in Antiretroviral Treated and Suppressed HIV+ Persons.* Manuscript Published. Role: Co-investigator.

ACTG 5323S: *The Functional Status, Inflammation, and Health Trajectories among Aging HIV-Infected Adults.* Ongoing. Role: Co-investigator.

ACTG PR 708: *Safety, Tolerability, and Effects of Probiotic VSL#3 on Gut Microbiome and Immune Activation Markers in HIV-1 Infected Subjects on Suppressed Antiretroviral Therapy: A Pilot Study.* In development. Role: Vice-chair.

Invited Presentations (Selected):

“Novel Therapeutic Vaccines for HIV-1 Infection”
Invited Speaker, Immune Mechanisms and HIV Disease Pathogenesis
Meeting, Cleveland OH, May 2002

“Yeast-based Vaccines for HIV-1 Infection”
Infectious Diseases Colloquium
Colorado State University, 4/2004

“EP HIV-1090: A Novel Therapeutic Vaccine for HIV-1 Infection”
Infectious Diseases Grand Rounds, UC Denver, February 2005

“Therapeutic Vaccines for HIV: A Bench-to-Bedside Experience”
Allergy Grand Rounds
National Jewish Medical Center, 5/2005

“A Phase I Safety and Immunogenicity Study of the Epimmune HIV-1 CTL
Epitope-based DNA Vaccine for Immunotherapy of HIV-1 Infected
Individuals Receiving HAART”
AIDS Vaccine 2005 Meeting
Montreal, Canada; September 2005

“Highlights from CROI 2006”
AIDS Education and Training Center
Annual Spring Clinical HIV Update, 2/2006

“Update on HIV Vaccines”
Colorado Women’s Health Advocacy Coalition
Women and HIV Prevention Forum, March 2006

“HIV-associated Dendritic Cell Dysfunction”
Human Immunology Group (HIG) Seminar, UC Denver, April 2006

“Therapeutic Vaccination against HIV-1”
Invited speaker for HIV Community Advisory Board, October 2006

“HIV Vaccines as Therapy”
HIV Symposium, Interscience Conference on Antimicrobial Agents and
Chemotherapy (ICAAC) meeting, San Francisco, CA, September 2006

“Dendritic Cells in HIV-1 Infection: Lessons learned, Questions raised”
Clinical Immunology Seminar, UC Denver, December 2007

“Update on HIV Vaccines: Outwitting a clever virus”
Invited speaker, Medical Grand Rounds, University of California at San
Diego, May 2007

Moderator for session at Conference on Retroviruses and Opportunistic
Infections (CROI) 2008, Los Angeles, CA, Feb. 25-28.
Session: “Primary HIV Infection, Early Treatment, and Immune-based
Therapies for Chronic Infection.”

“Update on HIV Vaccines”
Invited speaker for HIV Community Advisory Board (CAB), January 2008

“Vaccine Update from CROI”,
Invited speaker, Annual Spring Clinical HIV-1 Update, Denver, CO

3/12/2008

Moderator for session on “Aging and Inflammation” at national AIDS Clinical Trials Group (ACTG) meeting in December 2008.

“HIV in the Gut: A role for microbial translocation in HIV pathogenesis,” Gastroenterology Grand Rounds, UC Denver, 3/13/2009

Moderator for session at 16th Conference on Retroviruses and Opportunistic Infections (CROI) 2009, Montreal Canada, Feb. 8-11, “Recent Developments in Vaccines and Immune-based Therapies”

Moderator for session entitled “Antiretroviral therapy: Immune response, and inflammation” at national AIDS Clinical Trials Group (ACTG) Scientific Retreat, March 2009.

“HIV in the Gut: Defining Cellular Interactions that Drive HIV-1 Pathogenesis.” Invited speaker at UC Denver Mucosal Inflammation Program Research-in-Progress Seminar, October 2009.

Session moderator and presenter at national AIDS Clinical Trials Group (ACTG) meeting June 19, 2010 (Washington, DC), talk entitled “Adventures in Therapeutic Immunization: A View of the Forest, not just the Trees”

Session moderator on “Microbiome and Immunity” and presenter of talk entitled “Role of Commensal Bacteria in HIV-1 Pathogenesis” at the 11th Annual Colorado Immunology Conference, September 2010

Visiting professor lecture at Rush Medical Center May 18th, 2011, entitled “Role of Commensal Bacteria in HIV Mucosal Pathogenesis.”

Speaker at national ACTG Scientific Retreat at both Cure TSG and Inflammation TSG scientific sessions, March 2012, talk entitled: “CROI Update: Is There Hope for Therapeutic Vaccines?”

Speaker at HIV Community Advisory Board meeting, talk entitled “Therapeutic Vaccination for HIV Infection: Is there a role in the Cure Agenda?”, May 25, 2012, Denver, CO.

Invited speaker at meeting on Aging and HIV infection, talk entitled: “Mucosal Inflammation: A Role for Intestinal Epithelial Cell Damage and Microbial Translocation.” October 28, 2012. Rush University, Chicago, IL.

Infectious Diseases Grand Rounds, UCD, talk entitled: “How HIV Guts the Immune System: A Tale of Death and Inflammation”, October 2013.

Invited speaker for 1st International Workshop on Microbiome in HIV: Pathogenesis, Prevention, and Treatment. April 7-8, 2015. Bethesda. MD.

Invited speaker for 12th World Congress on Inflammation. August 8-12, 2015. Boston, MA.

Invited speaker for ID Week, October 7-11, 2015, San Diego, CA.

Invited speaker for 6th International Workshop on HIV & Aging, October 5-6, 2015 in Washington DC.

Invited to run session on HIV and the Microbiome for the ACTG Retreat in Boston, MA, February 2016

Invited speaker for the University of Washington Center for AIDS Research (CFAR) program for October 2016: "HIV and the Microbiome"

Review Committees: National Institute of Allergy and Infectious Diseases,
National Institutes of Health
Integrated Preclinical/Clinical AIDS Vaccine Development Program
Review Committee 6/2001

National Institute of Allergy and Infectious Diseases,
National Institutes of Health
Comprehensive International Program for Research on AIDS (CIPRA)
Review Committee 6/2002, 2/2003

National Institute of Allergy and Infectious Diseases,
National Institutes of Health
HIV Vaccine Research and Design Program
Review committee 3/2006

National Institute of Allergy and Infectious Diseases,
National Institutes of Health
Integrated Preclinical/Clinical AIDS Vaccine Development Program
Review committee 11/2006

National Institute of Allergy and Infectious Diseases,
National Institutes of Health
AIDS Research Review Committee (RCC) Study Section
Standing Member: 11/2007-11/2012

Member of NIAID AIDS Research Advisory Committee
Standing member: 11/2015 to present

Journal Reviewer: The journal *AIDS*, *Journal of Immunology*, *Blood*, *Journal of Virology*, *Journal of Infectious Diseases*, *Nature Biotechnology*, *AIDS Research and Human Retroviruses*, *Journal of Leukocyte Biology*, *Journal of Clinical Immunology*, *PLoS Pathogens*, *PLoS ONE*, *Clinical Infectious Diseases*.

Advisory Boards: - Advisor for Pharmexa-Epimmune, Bavarian-Nordic, Vical, Tanox
- Member of Organizing Committee for International Microbiome Workshop 2016

Data Safety Monitoring Boards:

- 1) Chair, DSMB for Bavarian-Nordic Phase I Therapeutic Vaccine Trial (HIV-MAG-001);
- 2) Chair, DSMB for L. Shapiro AAT Clinical Trial;
- 3) Safety monitor for P. Anderson Tenofovir study; Blood spot study.
- 4) DSMB member, Argos Therapeutics AGS-004-003 therapeutic vaccine protocol.

Major Research Interests:

1. Cellular immune response to HIV-1 and correlates of immune protection in early and

- chronic HIV-1 infection.
- 2. Development of novel prophylactic and therapeutic vaccines for HIV-1 infection
- 3. Immune reconstitution of HIV-1 infection
- 4. Interactions between HIV-1 and dendritic cells
- 5. Dendritic cell, T cell, and epithelial cell interactions in HIV-infected gut-associated lymphoid tissue (GALT)
- 6. HIV, aging, microbiome and mucosal immune function
- 7. Mechanisms of HIV-associated death in intestinal T cells
- 8. Role of Interferons in HIV pathogenesis

Extramural Research Support:

ACTIVE

Ongoing Research Support

R01 AI108404 Wilson (PI) 5/31/13 to 5/30/18
 Mechanisms of HIV-associated gut T cell Depletion.
 The goal of this project is to determine the host, microbial and virological determinants governing killing of gut CD4+ T cells by R5-tropic HIV-1.
 Role: Principal Investigator

R01 AI118983 Barker and Wilson (PIs) 6/15/2015 to 2/29/2020
 Switch from homeostatic to inflammatory cytokines by NK/ILC in HIV-infected gut.
 The goal of the project is to determine the impact of HIV-1 infection on gut natural killer /innate lymphoid cells.
 Role: Co- Principal Investigator

R56 AI116271 Santiago and Wilson (PIs) 04/16/2015 to 03/31/2016
 HIV-Associated Interferon Effector Mechanisms in the GALT.
 The goal of this project is to investigate the mechanism(s) underlying the protective and pathological role of IFN-alpha in mucosal HIV-1 infection.
 Role: Co-Principal Investigator.

R21 AI112418 Santiago (PI) 08/25/2014 to 07/31/2016
 Immunological impact of Tetherin retrovirus restriction.
 The goal of this project is to determine the role of Tetherin in retrovirus-specific CD4+ and CD8+ T cell responses.
 Role: Co-investigator.

UM1 AI069432 Benson (PI) 12/01/13 to 11/30/20
 Source:NIH/NIAID
 California-Colorado-Chennai-Durban (CD4) Collaborative Clinical Trials Unit (CTU)
 This is a program project grant that supports AIDS clinical trials at the University of Colorado.
 Role: Co-investigator

COMPLETED

R01 DK088663 (Wilson, PI)
 Source: NIDDK
 Mechanisms of HIV-associated Disruption of Intestinal Homeostasis.
 Role: Principal Investigator
 Award period: 07/01/2010 to 06/30/2015

UCD Proteomics Pilot Award (C.C. Wilson, S. Dillon, Co-PIs)

Source: UCD Proteomics Core
Pilot study to identify proteomic signatures, using SOMAscan technologies, which correlate with an inflammaging phenotype in HIV-infected subjects.
Award period: 02/02/2015 to 05/01/2015

K24 AI074343 (C. Wilson, PI)

Source: NIAID
Interface of Innate and Adaptive Immunity in HIV-1 Infection
Role: Principal Investigator
Total Award Period: 12/1/07-11/30/12

K24 AI074343 (C. Wilson)

Source: NIH/NIAID
Interface of Innate and Adaptive Immunity of HIV-1 Infection (ARRA Supplement)
Total Award Period: 09/22/09-08/31/11

R01 AI065275 (C. Wilson, PI)

Source: NIH/NIAID
HIV-related blood dendritic cell dysfunction
Role: Principal Investigator
Total Award Period: 06/15/06-05/31/10 (in no cost extension period)

P01 AI055356 (Connick)

Source: NIH/NIAID
Immunopathogenesis of Acute HIV-1 Infection
Role: Project Leader for Project 3 entitled "Role of HIV-1-specific Cellular Immune Responses in Mediating Virologic Control in Early HIV-1 Infection."
Total Award Period: 04/30/03-03/31/08

P01 AI48238 PAR-97-080 (R. Chesnut, Program P.I.)

Source: NIH/NIAID
Immunogenicity of DR-supermotif helper epitopes in HIV.
Role: Principal Investigator of Project 3 of Program
Project entitled "Epitope-based DNA Vaccines for AIDS Therapy"
Total Award Period: 8/15/2000-6/30/2005

R21 AI54192

Source: NIH/NIAID, Innovation Grant Program for AIDS Vaccine Research
Interactions between recombinant yeast and blood DCs
Role: Principal Investigator
Total Award Period: 2/15/03-1/31/05

P01 AI43664 PAR-97-080 P01 (Rinaldo, PI)

Role: Principal Investigator, Project 4
Source: NIH/NIAID
Novel HIV Therapies P01, Program Project entitled Antigen Delivery for Adjuvant HIV Immunotherapy
Project 4: Dendritic Cell Therapy for HIV-1: Use of Cytokines to Enhance T Cell Function.
Total Award Period: 9/30/98- 8/31/03

KO8AI01459-01 (Wilson, PI)

Dendritic Cell-Dependent Immunity to HIV-1
Source: NIH/NIAID
Role: Principal Investigator
Total Award Period: 4/1/97-3/31/02

Original Publications:

1. Taylor RP, Edberg JC, Kujala GA, Sloman AJ, **Wilson CC**, Cronin ME. The Interaction of Antibody/DNA Immune Complexes with Complement: Influence of Antibody Class and DNA Conformation. *Arthritis and Rheumatism* 1987; 30:176-185.
2. Hutchinson CM, **Wilson CC**, Reichart CA, Marsiglia VC, Zenilman JM, Hook EW. CD4 Lymphocyte Concentrations in Patients with Newly Identified HIV Infection Attending STD Clinics: Potential Impact on Publicly Funded Health Care Resources. *JAMA* 1991; 266 (2): 253-256.
3. **Wilson CC**, Wong JT, Girard DD, Merrill DP, Dyan M, An DD, Kalams SA, Johnson RP, Hirsch MS, D'Aquila RT, Walker BD. Ex-vivo Expansion of CD4+ T Lymphocytes from Human Immunodeficiency Virus Type-1 Infected Persons in the Presence of Combination Antiretroviral Agents. *J Infect Dis* 1995;172:88-96.
4. **Wilson CC**, Kalams SA, Wilkes BM, Ruhl DJ, Gao F, Hahn BH, Hanson IC, Luzuriaga K, Wolinsky S, Koup R, Buchbinder SP, Johnson RP, Walker BD. Overlapping Epitopes in Human Immunodeficiency Virus Type 1 gp120 Presented by HLA A, B, and C Molecules: Effects of Viral Variation on Cytotoxic T-Lymphocyte Recognition. *J Virol* 1997;71:1256-1264.
5. **Wilson CC**, Tueting T, Ma D, Haluszczak C, Lotze M, and Storkus WJ. Activation of Dendritic Cells by Surrogate T cell Interactions Leads to Enhanced Costimulation, Secretion of Th1-associated Cytokines, and CTL Inductive Capacity. *Advances in Experimental Medicine & Biology* 1997; 417:335-43.
6. Fan Z, Huang XL, Zheng L, **Wilson CC**, Borowski L, Liebmman J, Gupta P, Margolick J, Rinaldo C. Cultured blood dendritic cells retain HIV-1 antigen-presenting capacity for memory CTL during progressive HIV-1 infection. *Journal of Immunology* 1997; 159(10):4973-82.
7. Tueting T, **Wilson CC**, Martin DM, Kasamon YL, Rowles J, Ma DI, Slingluff CL, Wagner SN, van der Bruggen P, Baar J, Lotze MT, Storkus WJ. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN- α . *J Immunology* 1998; 160:1139-1147.
8. **Wilson CC**, Walter C, Olson, Thomas Tuting, Charles R. Rinaldo, Michael T. Lotze, Walter J. Storkus. HIV-1-specific cytotoxic T lymphocyte responses primed in vitro by blood-derived dendritic cells and Th1-biasing cytokines. *J Immunology* 1999; 162:3070-3078.
9. **Wilson CC**, R. Clark Brown, Deborah J. Ruhl, Barbara M. Wilkes, Bette T. Korber, Zareefa I. Burke, Katherine Luzuriaga, I. Celine Hanson, Susan Widmayer, Andrew Wiznia, Shiela Clapp, Arthur J. Ammann, Richard A. Koup, Steve M. Wolinsky, Bruce D. Walker and the Ariel Project Investigators. Frequent detection of CTL escape in perinatal HIV-1 transmission: The Ariel Project for the prevention of transmission of HIV from mother to infant. *Journal of Virology* 1999; 73(5):3975-3985.
10. Zheng L, Huang X-L, Fan Z, Borowski L, **Wilson CC**, Rinaldo CR. Delivery of HIV-1 proteins to human dendritic cells by liposomes activates HIV-1 specific memory CTL responses. *AIDS Research and Human Retroviruses* 1999; 15(11):1011-1020.
11. Hay CM, Ruhl DJ, Basgoz NO, **Wilson CC**, DePasquale MP, D'Aquila R, Walker BD. Defective in vivo activation of HIV-1-specific CTL in rapidly progressive HIV-1 infection. *Journal of Virology* 1999; 73(7):5509-5519.

12. **Wilson CC**, Palmer B, Southwood S, Sidney J, Higashimoto Y, Appella E, Chesnut R, Sette A, Livingston BD. Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper t-lymphocyte epitopes. *J Virol* 2001; 75(9):4195-207.
13. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC, **Wilson CC**. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. *Nat Med* 2001; 7:625-9.
14. Palmer B, Boritz E, Blyveis N, and **Wilson CC**. Discordance between frequency of HIV-1-specific IFN- γ -producing CD4⁺ T cells and HIV-1-specific lymphoproliferation in HIV-1-infected subjects with active viral replication. *J Virol* 2002; 76(12):5925-5936.
15. Barron MA, Blyveis N, Palmer B, MaWhinney S, and **Wilson CC**. Defects in Number and Surface Expression of Co-stimulatory Molecules in Both CD11c⁺ and CD11c⁻ Blood DCs in HIV-1-Infected Individuals. *Journal of Infectious Diseases* 2003; Jan. 1; 187(1):26-37.
16. Boritz EA, Palmer B, Livingston B, and **Wilson CC**. Diversity of HIV-p24-specific CD4⁺ T Cell Clones in the setting of Immune Reconstitution after Highly Active Antiretroviral Therapy (HAART). *Journal of Immunology* 2003; Jan. 15, 170(2):1106-16.
17. **Wilson CC**, McKinney D, Anders M, MaWhinney M, Forster J, Crimi C, Southwood S, Sette A, Chesnut R, Newman MJ and Livingston BD. Development of a DNA Vaccine Designed to Induce Cytotoxic T Lymphocyte Responses to Multiple Conserved Epitopes in HIV-1. *J Immunol.* 2003; Nov 15;171(10):5611-23.
18. Palmer B, Boritz W, and **Wilson CC**. Effects of sustained HIV-1 plasma viremia on HIV-1-specific CD4⁺ T cell maturation and function. *J Immunology* 2004; 172: 3337-3347.
19. McKinney DM, Skvoretz R, Livingston BD, **Wilson CC**, Anders M, Chesnut RW, Sette A and Newman MJ. Recognition of variant HIV-1 epitopes from diverse viral subtypes by vaccine-induced CTL. *J. Immunology* 2004; 173(3):1941-50.
20. Boritz E, Palmer B, and **Wilson CC**. Human Immunodeficiency Virus Type 1-specific CD4⁺ T Cells that Proliferate *In Vitro* Detected from Most Viremic Subjects and Associated with Lower Plasma HIV-1 Loads. *J. Virology* 2004; Nov;78(22):12638-46.
21. McCarter MD, Clarke J, Richter D, **Wilson CC**. Melanoma skews dendritic cells to facilitate a T helper 2 profile. *Surgery* 2005; 138:321-8.
22. Palmer B, Blyveis N, Fontenot AP, and **Wilson CC**. Functional and phenotypic characterization of CD57⁺ T cells and their association with HIV-1-induced T cell dysfunction. *J Immunology* 2005; 175(12):8415-23.
23. Fontenot AP, Palmer BE, Sullivan AK, Joslin FG, **Wilson CC**, Maier LA, Newman LS, Kotzin BL. Frequency of Beryllium-specific, central memory CD4⁺ T cells in blood determines proliferative response. *J Clin Invest.* 2005; 115(10):2886-93.
24. Koeppe JR, Campbell TP, Rapaport R, and **Wilson CC**. HIV-1 specific CD4⁺ T cell responses are not associated with significant viral epitope variation in persons with persistent plasma viremia. *J AIDS* 2006; 41(2):140-8.
25. Barron MA, Blyveis N, Pan SC, and **Wilson CC**. Human Dendritic Cell Interactions with Whole Recombinant Yeast: Implications for HIV-1 Vaccine Development. *J Clin Immunology* 2006; May, 26(3):251-64.

26. Boritz E, Rapaport EL, Campbell TP, Koeppe JR, and **Wilson CC**. CD4⁺ T Cell Targeting of HIV-1 Peptide Sequences Present *In Vivo* during Chronic, Progressive HIV-1 Disease. *Virology* 2007; Apr 25, 361(1):34-44.
27. D'Souza M, Fontenot AP, Mack DG, Lozupone C, Dillon S, Meditz A, **Wilson CC**, Connick E, Palmer B. PD-1 Expression on HIV-specific CD4⁺ T Cells is Driven by HIV Replication. *J Immunology* 2007; Aug 1, 179(3):1979-87.
28. McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W, **Wilson CC**, Palmer B, Gonzalez R. Immunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients. *Annals of Surgical Oncology* 2007; June 26.
29. Baumgartner J, **Wilson C**, Palmer B, Richter D, Banerjee A, McCarter M. Melanoma Induces Immunosuppression by Up-regulating FOXP3(+) Regulatory T Cells. *J Surg Res* 2007; 141(1):72-7.
30. Connolly NC, Whiteside TL, **Wilson CC**, Kondragunta V, Rinaldo CR, Riddler SA. Therapeutic Immunization with HIV-1 Peptide-Loaded Dendritic Cells is Safe and Immunogenic in HIV-1-Infected Individuals. *Clin Vaccine Immunology* 2008; Feb;15(2):284-92.
31. Dillon S, Robertson K, Pan S, MaWhinney S, Meditz A, Folkvord J, Connick E, McCarter M, **Wilson CC**. Plasmacytoid and myeloid dendritic cells display an activated but incomplete maturation phenotype and accumulate in lymphoid tissue during chronic, asymptomatic Human Immunodeficiency Virus Type 1 infection. *J AIDS* 2008; Jan. 31.
32. **Wilson CC**, Newman MJ, Livingston BD, MaWhinney S, Forster JE, Scott J, Schooley RT, Benson CA. Clinical phase 1 testing of the safety and immunogenicity of an epitope-based DNA vaccine in human immunodeficiency virus type 1-infected subjects receiving highly active antiretroviral therapy. *Clin Vaccine Immunology* 2008; Jun;15(6):986-94.
33. Rawleigh Howe, Stephanie Dillon, Lisa Rogers, Brent Palmer, Samantha MaWhinney, Naomi Blyveis, Rick Schlichtemeier, Michelle D'Souza, Laura Ingoldby, Jeri E.F. Harwood, Cornelis Rietmeijer, Graham Ray, Elizabeth Connick, and **Cara C. Wilson**. Phenotypic and Functional Characterization of HIV-1-specific CD4⁺CD8⁺ Double Positive T cells in Early and Chronic HIV-1 Infection. *JAIDS* 2009; Apr 15;50(5):444-56.
34. John A. Mengshol, Lucy Golden-Mason, Nicole Castelblanco, KyungAh Im, Stephanie M. Dillion, **Cara C. Wilson**, Hugo R. Rosen for the Virahep-C Study Group. Dendritic Cell Chemokine Receptor Expression and Functional Chemotaxis in Chronic HCV: Associations with Antiviral Treatment Outcomes. *Gut* 2009; Jul;58(7):964-73.168948.
35. Rawleigh Howe, Stephanie Dillon, Lisa Rogers, Martin McCarter, Caleb Kelly, Ricardo Gonzalez, and **Cara C. Wilson**. Evidence for Dendritic Cell-Dependent CD4⁺ T Helper-1 Type Responses to Commensal Bacteria in Normal Human Intestinal Lamina Propria. *Clin Immunology* 2009; Jan 25.
36. Baumgartner JM, Gonzalez R, Lewis KD, Robinson WA, Richter DA, Palmer BE, **Wilson CC**, McCarter MD. Increased survival from stage IV melanoma associated with fewer regulatory T Cells. *J Surg Res*. 2009; Jun 1;154 (1):13-20.
37. S.M. Dillon, L.M. Rogers, R. Howe, L. A. Hostetler, J. Buhrman, M.D. McCarter and **C.C. Wilson**. Human intestinal lamina propria CD1c⁺ dendritic cells display an activated

- phenotype at steady state and produce IL-23 in response to TLR7/8 stimulation. *J Immunology* 2010, Jun 15;184(12):6612-21.
38. Kassu A, Marcus RA, D'Souza M, Kelly-McKnight E, Akkina R, Fontenot A, **Wilson, CC**, and Palmer, BE. Regulation of virus-specific CD4+ T cell function by multiple costimulatory receptors during chronic HIV infection. *J Immunol.* 2010; Sep 1;185(5):3007-18.
 39. Dillon, S.M, Friedlander, L.J, Rogers, L.M, Meditz, A.L, Folkvord, J.M, Connick, E., Martin D. McCarter, M.D and **Wilson, C.C.** Blood Myeloid Dendritic Cells from HIV-1-infected Individuals Display a Pro-apoptotic Profile Characterized by Decreased Bcl-2 levels and by Caspase-3⁺ Frequencies that are Associated with Levels of Plasma Viremia and T Cell Activation in an Exploratory Study. *J. Virology* 2011; 85: 397-409.
 40. Taiwo B, Zheng L, Gallien S, Matining RM, Kuritzkes DR, **Wilson CC**, Berzins BI, Acosta EP, Bastow B, Kim PS, Eron JJ Jr; ACTG A5262 Team. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naïve HIV-1-infected patients (ACTG A5262). *AIDS* 2011; Nov 13; 25(17):2113-22.
 41. J.M. Baumgartner, K. R. Jordan, L-J Hu, **C.C. Wilson**, A. Banerjee, and M.D. McCarter. DC Maturation and Function are Not Altered by Melanoma-Derived Immunosuppressive Soluble Factors. *J Surg Research* 2012; Jul; 176(1):301-8.
 42. Katherine Tassiopoulos, Alan Landay, Ann C. Collier, Elizabeth Connick, Steven G. Deeks, Peter Hunt, Dorothy E. Lewis, **Cara Wilson**, Ronald Bosch. CD28-Negative CD4+ and CD8+ T-cells in ART-Naïve HIV-Infected Adults Enrolled in ACTG Studies. *J Infect Dis.* 2012; Jun; 205 (11):1730-8.
 43. Stephanie M. Dillon, Jennifer A. Manuzak, Amanda K. Leone, Eric J. Lee, Lisa M. Rogers, Martin D. McCarter, **Cara C. Wilson**. HIV-1 infection of human intestinal lamina propria CD4⁺ T cells *in vitro* is enhanced by exposure to commensal *Escherichia coli*. *J Immunol.* 2012; Jul 15;189(2):885-96.
 44. Jennifer Manuzak, Stephanie Dillon, **Cara Wilson**. Differential IL-10 and IL-23 production by human blood monocytes and dendritic cells in response to commensal enteric bacteria. *Clin Vaccine Immunol.* 2012; Aug;19 (8):1207-17.
 45. Ivona Pandrea, Elaine Cornell, **Cara Wilson**, Ruy M. Ribeiro, Dongzhu Ma, Jan Kristoff, Cuiling Xu, George S. Haret-Richter, Anita Trichel, Cristian Apetrei, Alan Landay and Russell Tracy. Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. *Blood* 2012; Aug 16;120(7):1357-66.
 46. Erlandson KM., Allshouse AA., Jankowski CM, Lee EJ, Rufner KM, Palmer BP, **Wilson CC**, MaWhinney S, Kohrt WM, Campbell TB. Association of Functional Impairment with Inflammation and Immune Activation in HIV-1- Infected Adults on Effective Antiretroviral Therapy. *J Infect Dis* 2013; Jul 15; 208(2):249-59.
 47. Taiwo, Babafemi; Matining, Roy; Zheng, Lu; Lederman, Michael; Rinaldo, Charles; Kim, Peter; Berzins, Baiba; Kuritzkes, Dan; Jennings, Amy; Eron, Joseph; **Wilson, Cara**. Associations of T cell Activation and Inflammatory Biomarkers with Virologic Response to Darunavir/ritonavir plus Raltegravir Therapy. *Journal of Antimicrobial Therapy* 2013; Aug; 68(8):1857-61.
 48. Manuzak, J.A., Dillon, S.M., Lee, E.J., Dong, Z.M., Hecht, D.K., and **Wilson, C.C.** Increased *Escherichia coli*-Induced Interleukin-23 Production by CD16⁺ Monocytes Correlates with Systemic Immune Activation in Untreated HIV-1-Infected Individuals. *J.*

49. Gustafson CE, Higbee D, Yeckes A, **Wilson C**, de Zoeten E, Jedlicka P, Janoff EN. Limited Expression of APRIL and its Receptors Prior to Intestinal IgA Plasma Cell Development During Human Infancy. *Mucosal Immunology* 2014; May; 7(3):467-77.
50. Dillon, S.M., Lee, E.J., Bramante, J.M., Barker, E., and **Wilson, C.C.** The Natural Killer Cell Interferon-gamma Response to Bacteria is Diminished in Untreated HIV-1 Infection and Defects Persist Despite Viral Suppression. *J. Acquir. Immune Defic. Syndr.* 2014; Mar 1;65(3):259-67.
51. Dillon, S.M., Lee, E.J., Kotter, C.V., Austin, G.L., Dong, Z., Hecht, D.K., Gianella, S., Siewe, B., Smith, D.M., Landay, A.L, Robertson, C.E., Frank, D.N., and **Wilson, C.C.** An altered intestinal mucosal microbiome in HIV-1 infection is associated with mucosal and systemic immune activation and endotoxemia. *Mucosal Immunology* 2014; Jul;7(4):983-94.
52. Steele AK, Lee EJ, Manuzak JA, Dillon SM, Beckham JD, McCarter MD, Santiago ML, **Wilson CC**. Microbial exposure alters HIV-1-induced mucosal CD4+ T cell death pathways ex vivo. *Retrovirology* 2014; Feb 4;11:14.
53. Li JZ, Chapman B, Charlebois P, Hofmann O, Weiner B, Porter AJ, Samuel R, Vardhanabhuti S, Zheng L, Eron J, Taiwo B, Zody MC, Henn MR, Kuritzkes DR, Hide W; ACTG A5262 Study Team, **Wilson CC**, Berzins BI, Acosta EP, Bastow B, Kim PS, Read SW, Janik J, Meres DS, Lederman MM, Mong-Kryspin L, Shaw KE, Zimmerman LG, Leavitt R, De La Rosa G, Jennings A. Comparison of illumina and 454 deep sequencing in participants failing raltegravir-based antiretroviral therapy. *PLoS One.* 2014 Mar 6;9(3):e90485. doi: 10.1371/journal.pone.0090485. eCollection 2014. PMID:24603872.
54. Kiene M, Rethi B, Jansson M, Dillon S, Lee E, Lantto R, **Wilson C**, Pöhlmann S, Chiodi F. Toll-Like Receptor 3 Signalling Up-Regulates Expression of the HIV Co-Receptor G-Protein Coupled Receptor 15 on Human CD4(+) T Cells. *PLoS ONE* 2014; 18;9(2):e88195.
55. Amanda K Steele, Eric J Lee, Brian Vestal, Daniel Hecht, Zachary Dong, John Koeppe, and **Cara C Wilson**. Contribution of Intestinal Damage, Microbial Translocation and HIV status to a Plasma Biomarker Inflammaging Signature. *PLoS ONE* 2014, May 12;9(5):e97171.
56. J. Kristoff, G. Haret-Richter, D. Ma, R.M. Ribeiro, C. Xu, E. Cornell, J.L. Stock, T. He, A.D. Mobley, S. Ross, A. Trichel, **C. Wilson**, R.Tracy, A. Landay, C. Apetrei, and I. Pandrea. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. *J Clin Invest* 2014; Jun 2 ; 124(6):2802-6. PMID:24837437.
57. Allan R Tenorio, Yu Zheng, Ronald J Bosch, Supriya Krishnan, Benigno Rodriguez, Peter W Hunt, Jill Plants, Arjun Seth, **Cara C Wilson**, Steven G Deeks, Michael M Lederman, Alan L Landay. Soluble markers of inflammation and coagulation, but not T-cell activation, are predictors of non-AIDS-defining morbid events during suppressive antiretroviral treatment. *J Infect Dis* 2014; Oct 15;210(8):1248-59. PMID 24795473.
58. Tenorio AR, Chan ES, Bosch RJ, Macatangay BJ, Read SW, Yesmin S, Taiwo B, Margolis DM, Jacobson JM, Landay AL, **Wilson CC**; for the A5286 Team. Rifaximin Has a Marginal Impact on Microbial Translocation, T-cell Activation and Inflammation in HIV-Positive Immune Non-responders to Antiretroviral Therapy - ACTG A5286. *J Infect Dis* 2014; Sep 11.

59. Sandler NG, Zhang X, Bosch RJ, Funderburg NT, Choi AI, Robinson JK, Fine DM, Coombs RW, Jacobson JM, Landay AL, Douek DC, Tressler R, Read SW, **Wilson CC**, Deeks SG, Lederman MM, Gandhi RT; on behalf of the AIDS Clinical Trials Group A5296 Team. Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection. *J Infect Dis* 2014; Nov 15; 210(10):1549-54.
60. Sattler F, He J, Letendre S, **Wilson C**, Sanders C, Heaton R, Ellis R, Franklin D, Aldrovandi G, Marra CM, Clifford D, Morgello S, Grant I, Mccutchan JA; for the CHARTER Group. Abdominal Obesity Contributes to Neurocognitive Impairment in HIV Infected Patients with Increased Inflammation and Immune Activation. *J Acquir Immune Defic Syndr*. 2014; Dec 2.
61. Castillo-Mancilla JR¹, Meditz A, **Wilson C**, Zheng JH, Palmer BE, Lee EJ, Gardner EM, Seifert S, Kerr B, Bushman LR, MaWhinney S, Anderson PL. Reduced Immune Activation During Tenofovir-Emtricitabine Therapy in HIV-Negative Individuals. *J Acquir Immune Defic Syndr*. 2015 Apr 15;68(5):495-501.
62. Erlandson KM, Allshouse AA, Rapaport E, Palmer BE, **Wilson CC**, Weinberg A, MaWhinney S, Campbell TB. Physical function impairment of older, HIV-infected adults is associated with cytomegalovirus immunoglobulin response. *AIDS Res Hum Retroviruses*. 2015 Sep;31(9):905-12. doi: 10.1089/AID.2015.0085. Epub 2015 Jul 8. PMID:26061347.
63. Pandrea I, Landay A, **Wilson C**, Stock J, Tracy R, Apetrei C. Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities. *Curr HIV/AIDS Rep*. 2015 Mar;12(1):54-67. doi: 10.1007/s11904-014-0245-5.
64. Harper MS, Guo K, Gibbert K, Lee EJ, Dillon SM, Barrett BS, McCarter MD, Hasenkrug KJ, Dittmer U, **Wilson CC**, Santiago ML. Interferon- α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection: Expression, Potency and Effector Mechanisms. *PLoS Pathog*. 2015 Nov 3;11(11):e1005254. doi: 10.1371/journal.ppat.1005254. eCollection 2015 Nov.
65. Dillon SM, Lee EJ, Kotter CV, Austin GL, Gianella S, Siewe B, Smith DM, Landay AL, McManus MC, Robertson CE, Frank DN, McCarter MD, **Wilson CC**. Gut dendritic cell activation links an altered colonic microbiome to mucosal and systemic T-cell activation in untreated HIV-1 infection. *Mucosal Immunol*. 2016 Jan;9(1):24-37. doi: 10.1038/mi.2015.33. Epub 2015 Apr 29.
66. Jacobson JM, Zheng L, **Wilson CC**, Tebas P, Matining RM, Egan MA, Eldridge J, Landay AL, Clifford DB, Luetkemeyer AF, Tiu J, Martinez AL, Janik J, Spitz TA, Hural J, McElrath J, Frahm N; ACTG A5281 Protocol Team. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection. *J Acquir Immune Defic Syndr*. 2016 Feb 1;71(2):163-71. doi: 10.1097/QAI. PMID: 26761518.
67. Pandrea I, Xu C, Stock JL, Frank DN, Ma D, Policicchio BB, He T, Kristoff J, Cornell E, Haret-Richter GS, Trichel A, Ribeiro RM, Tracy R, **Wilson C**, Landay AL, Apetrei C. Antibiotic and Antiinflammatory Therapy Transiently Reduces Inflammation and Hypercoagulation in Acutely SIV-Infected Pigtailed Macaques. *PLoS Pathog*. 2016 Jan 14;12(1):e1005384. doi: 10.1371/journal.ppat.1005384. PMID:26764484.

68. Dillon SM, Lee EJ, Donovan AM, Guo K, Harper MS, Frank DN, McCarter MD, Santiago ML, **Wilson CC**. Enhancement of HIV-1 infection and intestinal CD4+ T cell depletion ex vivo by gut microbes altered during chronic HIV-1 infection. *Retrovirology*. 2016 Jan 14;13(1):5. doi: 10.1186/s12977-016-0237-1. PMID:26762145
69. Jeffrey M. Jacobson, Steven E. Bosinger, Minhee Kang, Pablo Belaunzaran-Zamudio, Roy M. Matining, **Cara C. Wilson**, Charles Flexner, Brian Clagett, Jill Plants, Sarah Read, Lynette Purdue, Laurie Myers,¹ Linda Boone, Pablo Tebas, Princy Kumar, David Clifford, Daniel Douek, Guido Silvestri, Alan L. Landay, Michael M. Lederman, for the AIDS Clinical Trial Group A5258 Protocol Team. The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. *AIDS Research and Human Retroviruses* 2016, March 2. PMID: 26935044.
70. Kerry J. Lavender*, Kathrin Gibbert*, Karin E. Peterson, Erik Van Dis, Sandra Francois, Tyson Woods, Ronald J. Messer, Ali Gawanbacht, Janis A. Muller, Jan Munch, Katie Phillips, Brent Race, Michael S. Harper, Kejun Guo, Eric J. Lee, Mirko Trilling, Hartmut Hengel, Jacob Piehler, Jens Verheyen, **Cara C. Wilson**, Mario L. Santiago, Kim J. Hasenkrug and Ulf Dittmer. 2016. Interferon alpha subtype-specific suppression of HIV-1 infection *in vivo*. *J Virol*, in press.

Review Articles:

1. **Wilson CC**, and Hirsch MS. Combination Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type-1 Infection. *Proceedings of the Association of American Physicians*. 107(1):19-27, 1995.
2. Lotze MT, Hellerstedt B, Stolinski L, Tueting T, **Wilson CC**, Kinzler D, Vu H, Rubin JT, Storkus W, Tahara H, Elder E, Whiteside T. The Role of Interleukin-2, Interleukin-12, and Dendritic Cells in Cancer Therapy. *Cancer J Sci Am* 1997; 3:S109-S114.
3. Tueting T, Zorina T, Ma D, **Wilson CC**, DeCesare CM, Deleo AB, Lotze MT, Storkus WJ. Development of Dendritic Cell-Based Genetic Vaccines for Cancer. *Advances in Experimental Medicine & Biology*. 417:511-8, 1997.
4. Sette A, Chesnut R, Livingston B, **Wilson C**, Newman M. HLA-binding peptides as a therapeutic approach for chronic HIV infection. *IDrugs*. 2000 Jun;3(6):643-8.
5. Stubbs AC and **Wilson CC**. Recombinant yeast as a vaccine vector for the induction of cytotoxic T-lymphocyte responses. *Curr Opin Mol Ther* 2002; 4(1):35-40.
6. Newman MJ, McKinney D, Chesnut R, Sette A, **Wilson CC**, and Livingston B. Design and construction of T-lymphocyte epitope-based therapeutic HIV-1 vaccines. *Clinical and Applied Immunology Reviews*. 2003. 3:157-166.
7. Connick E, MaWhinney S, **Wilson CC**, Campbell TB. Challenges in the study of patients with HIV type 1 seroconversion. *Clin Infect Dis*. 2005 May 1;40(9):1355-7.

Books:

1. Dendritic Cells, copyright 1999 by Academic Press, Michael T. Lotze and Angus W. Thompson, editors. Contributing author to Chapter 25, entitled "Dendritic Cell Therapy of Cancer and HIV Infection".
2. Dendritic Cells, copyright 2001 by Academic Press, Michael T. Lotze and Angus W.

Thompson, editors. Author of chapter entitled “Dendritic Cell Therapy of HIV Infection”.

3. Clinical Immunology, copyright 2001 by Harcourt Publishers Limited. Co-author with Bruce Walker on chapter entitled “Acquired Immunodeficiency Syndrome”.
4. Infectious Diseases, copyright 2009, Cohen, Powderly, and Opal, editors. Coauthor of chapter entitled “Host Responses to Infection” with Dr. Robert Schooley.
5. Encyclopedia of AIDS, by Springer Publishers, edited by Thomas Hope, Douglas D. Richman and Mario Stevenson. Lead author on two chapters on The Gut as a Reservoir for HIV (and SIV), in press 2016.

Meeting Abstracts (selected):

- 2016 *Altered Gut Microbes Enhance Mucosal CD4 T Cell Infection and Depletion Ex Vivo*. Stephanie M. Dillon, Eric J. Lee, Andrew M. Donovan, Kejun Guo, Michael S. Harper, Daniel N. Frank, Martin D. McCarter, Mario L. Santiago, **Cara C. Wilson**. CROI 2016. Boston, MA.
- 2016 *Proteomic Profiles Associated with an Inflammaging Phenotype During HIV-1 Infection*. Stephanie M. Dillon, Eric J. Lee, Brian Vestal, Tzu L. Phang, Michael G. Edwards, **Cara C. Wilson**. CROI 2016. Boston, MA
- 2016 *Enhanced Replication of Transmitted/Founder HIV-1 in Gut CD4 T cells*. Lee EJ, Guo K, Harper M, Dillon S, McCarter M, Barrett B, Iyer S, Hahn B, **Wilson C**, Santiago M. CROI 2016. Boston, MA
- 2016 *Expression and Potency of IFN α Subtypes in an Ex Vivo Model of Acute HIV-1 Infection*. Mario L. Santiago, Michael S. Harper, Kejun Guo, Kathrin Gibbert, Eric L. Lee, Stephanie M. Dillon, Martin D. McCarter, Kim J. Hasenkrug, Ulf Dittmer, **Cara Wilson**. CROI 2016. Boston, MA
- 2015 *The short chain fatty acid butyrate reduces HIV-1 and pathobiont-associated increases in intestinal myeloid dendritic cell and T cell activation*. Stephanie Dillon, Jon Kibbie, Eric Lee, Charles Robertson, Daniel N. Frank, Martin McCarter, **Cara C. Wilson**. 1st International Workshop on Microbiome in HIV. April 2015. Bethesda, MD.
- 2015 *Butyrate reduces pathobiont-associated HIV-1 infection and activation of gut T cells*. Jon Kibbie, Stephanie Dillon, Eric Lee, Chuck Robertson, Daniel N. Frank, Martin McCarter, **Cara C. Wilson**. Accepted at 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, WA, March 2015.
- 2015 *Characterization of Interferon- α subtypes in the LPAC model*. Michael Harper, Kathrin Gibbert, Eric Lee, Kejun Guo, Stephanie Dillon, Martin McCarter, Ulf Dittmer, **Cara Wilson**, and Mario Santiago. Accepted at 2015 Conference on Retroviruses and Opportunistic Infections. Seattle, WA, March 2015.
- 2014 *Rifaximin Has Marginal Impact on Immune Activation in Immunologic Nonresponders to ART - ACTG 5286*. A.R. Tenorio, **C.C. Wilson**, E. Chan, R.J. Bosch, B.J. Macatangay, S. Yesmin, S. Read, D.M. Margolis, J.M. Jacobson, A.L. Landay on behalf of ACTG 5286 Team. 2014 Conference on Retroviruses and Opportunistic Infections. Boston, MA, March 2015.
- 2014 *Dysregulated Gut Dendritic Cells Correlate with T cell Activation During Untreated HIV*

- Infection*. Dillon SM, Lee EJ, Austin, GL, Gianella, S, **Wilson CC**. 2014 Conference on Retroviruses and Opportunistic Infections. Boston, MA, March 2015.
- 2013 *The Contribution of Intestinal Epithelial Cell damage, Microbial Translocation, and HIV status to an Inflammaging Phenotype*. Amanda K Steele, Eric J Lee, Zachary Dong, Brian Vestal, John Koeppe, and **Cara C Wilson**. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 2013.
- 2013 *IFN- γ -producing Rectal γ/δ T cells are Increased in Untreated HIV-1 Infection and Correlate with T Cell Activation and Microbial Translocation*. Stephanie Dillon^{1*}, Eric Lee¹, Gregory Austin, Zachary Dong, Kevin Rufner, Sara Gianella Weibel, Davey Smith, **Cara C. Wilson**. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA, March 2013.
- 2012 *Association between Markers of Immune Activation, Inflammation, Coagulation and Virologic Failure in ACTG A5262: A Single Arm Study of Darunavir/Ritonavir Plus Raltegravir in Treatment-Naïve HIV-1-Infected Patients*. **Cara Wilson**, Roy Matining, Joseph Eron, Lu Zheng, Charles Rinaldo, Michael Lederman, Daniel Kuritzkes, Amy Jennings, Peter Kim, Babafemi Taiwo and A5262 Study Team. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, March 2012.
- 2012 *Commensal E.coli Enhance Depletion of Intestinal Lamina Propria CD4⁺ T Cells by R5 tropic HIV-1_{BaL} Ex Vivo*. Amanda Leone, Stephanie Dillon, Eric Lee, Martin McCarter, Mario Santiago and **Cara Wilson**. HIV Vaccines Keystone Symposia, Keystone CO, March 2012.
- 2012 *Elevated iFABP and Biomarkers of Microbial Translocation in HIV-Infected Subjects on Suppressive ART*. Kevin M. Rufner M.D. M.P.H., Eric E. Lee M.S., Zachary M. Dong B.A., Kristine M. Erlandson M.D., **Cara C. Wilson** M.D. HIV Vaccines Keystone Symposia, Keystone CO, March 2012.
- 2012 *Blood Natural Killer Cell IFN- γ Responses to Commensal Bacteria are Altered in HIV-1 Infection*. Stephanie Dillon, Eric Lee, Julia Bramante, Edward Barker, **Cara C. Wilson**. HIV Vaccines Keystone Symposia, Keystone CO, March 2012.
- 2011 *Commensal Escherichia coli Bacteria Enhance HIV-1 Replication and Infection of IL-17-producing CD4 T cells in Human Intestinal Lamina Propria Mononuclear Cell Cultures*. Stephanie Dillon, Lisa Rogers, Jennifer Manuzak, Martin McCarter & **Cara Wilson**. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA. 2011.
- 2011 *HIV Infection Alters the Peripheral Blood Cytokine Response to Innate Stimulation with Escherichia coli and TLR7/8 Ligand*. Jennifer Manuzak, Stephanie Dillon, **Cara Wilson**. 18th Conference on Retroviruses and Opportunistic Infections, Boston, MA. 2011.
- 2010 *Blood Myeloid Dendritic Cells from HIV-1-infected Individuals Display a Pro-apoptotic Profile That Increases With Disease Progression*. Stephanie Dillon, Laura Friedlander, Lisa Rogers, Amie Meditz, Joy Folkvord, Elizabeth Connick, Martin McCarter, **Cara Wilson**. Poster at 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA.
- 2010 *Dysfunction of HIV-Specific CD4⁺ T Cells is Associated with Elevated Concurrent Expression of Multiple Inhibitory Receptors*. Afework Gizaw, Michelle D'Souza, Roland Marcus, Elizabeth Kelly-McKnight, **Cara Wilson**, Ramesh Akkina, Andrew P. Fontenot, Brent E. Palmer. Poster at 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA.

- 2010 *Coagulation and inflammation biomarkers correlate with disease progression in SIV infections.* Ivona Pandrea, **Cara Wilson**, Ruy Ribeiro, Cristian Apetrei, Alan Landay, Russell Tracy. Poster at 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA.
- 2010 *The presence of commensal bacteria enhances HIV-1 infection of human lamina propria T cells.* Stephanie Dillon, Martin McCarter, **Cara C. Wilson**. Poster at 10th Annual Colorado Immunology Conference, Glenwood Springs, CO, USA.
- 2010 *Coagulation and Inflammation Biomarkers Predict Disease Progression in SIV-infected Nonhuman Primates.* Ivona Pandrea, **Cara Wilson**, Ruy Ribeiro, Cristian Apetrei, Alan Landay, Russell Tracy. Selected for oral presentation, 28th Annual Symposium on Nonhuman Primate Models, October 19-22, 2010, New Orleans, Louisiana.
- 2010 *Pro-inflammatory Blood Myeloid Dendritic Cell Cytokine Responses to Commensal Enteric Bacteria are Regulated by IL-10.* Jennifer Manuzak, Stephanie Dillon, Lisa Rogers, Toni Schwarz, Miriam Estin, **Cara Wilson**. Poster at 10th Annual Colorado Immunology Conference, Glenwood Springs, CO, USA.
- 2009 *Stimulating human lamina propria CD1c⁺ dendritic cells through TLR7/8 alters intestinal immune homeostasis by inducing IL-23 production.* Stephanie Dillon, Lisa Rogers, Rawleigh Howe, Lydia Hostetler, Jonathan Buhrman, Martin McCarter, **Cara Wilson**. Poster at 9th Annual Colorado Immunology Conference, Estes Park, CO, USA.
- 2009 *The Regulatory IL-10 Response of Blood Myeloid Dendritic Cells to E. coli is Suppressed by Co-stimulation with a Viral TLR7/8 Ligand.* Jennifer Manuzak, Stephanie Dillon, Lisa Rogers, Toni Schwarz, Miriam Estin, **Cara Wilson**. Poster at 9th Annual Colorado Immunology Conference, Estes Park, CO, USA.
- 2008 *Phenotypic and Functional Characterization of Human Intestinal Dendritic Cells: Breaking Immune Tolerance Through TLR7/8 Signaling.* Stephanie Dillon, Lisa Rogers, Rawleigh Howe, Lydia Hostetler, Jonathan Buhrman, Ricardo Gonzalez, Martin McCarter, **Cara Wilson**. Poster at Denver Translational Immunology Symposium, Denver, CO, USA.
- 2008 *Activated Plasmacytoid and Myeloid Dendritic Cells Accumulate in Lymphoid Tissue during Asymptomatic, Chronic HIV-1 Infection.* Stephanie Dillon, Kathryn Robertson, Samuel Pan, Samantha MaWhinney, Amie Meditz, Joy Folkvord, Elizabeth Connick, Martin McCarter, **Cara Wilson**. Poster at 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA.
- 2007 *Polarized Production of IL-2 by HIV-1-specific CD8⁺ T Cells in Subjects with Acute and Recent HIV-1 Infection.* **Cara Wilson**, Stephanie Dillon, Rick Schlichtemeier, Jeri Forster, Samantha MaWhinney, Cornelieus Rietmeijer, Graham Ray, and Elizabeth Connick. Poster at 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA.
- 2007 *PD-1 Expression on HIV-specific CD4⁺ T Cells is Driven by HIV Replication and is Associated with T-cell Dysfunction.* M D'Souza, A Fontenot, D Mack, S Dillon, A Meditz, **C Wilson**, E Connick, and B Palmer. Oral presentation at 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA.
- 2007 *Phenotypic and Functional Characterization of HIV-1-specific CD4⁺CD8⁺ T Cells in Subjects with Primary HIV-1 Infection.* Rawleigh Howe, Stephanie Dillon, Jeri E. Forster, Rick Schlichtemeier, Cornelis Rietmeijer, Graham Ray, Samantha MaWhinney, Brent Palmer, Elizabeth Connick, and **Cara Wilson**. Poster at 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, USA.

- 2006 *CD4+ T cell targeting of HIV-1 peptide sequences present in vivo during chronic, progressive HIV-1 disease.* Eli Boritz, Eric L. Rapaport, Thomas Campbell, John R. Koeppe, and **Cara C. Wilson**. Poster at 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO USA.
- 2006 *Dendritic Cell-HIV Peptide Therapeutic Vaccination Is Safe and Immunogenic in HIV-infected Subjects with Virologic Suppression.* Connolly NC, Rinaldo CR, Whiteside TL, **Wilson CC**, Kondragunta, V, Riddler SA. Poster at 13th Conference on Retroviruses and Opportunistic Infections, Denver, CO USA.
- 2006 *Dendritic Cell Dysfunction During HIV-1 Infection.* Stephanie Dillon, Kathryn Robertson, Samuel Pan, Samantha MaWhinney, Amie Meditz, Joy Folkvord, Elizabeth Connick, Martin McCarter, **Cara Wilson**. Poster at 7th Annual Colorado Immunology Conference, Breckenridge, CO, USA.
- 2005 *Immunogenicity of a multi-Epitope-Based DNA Vaccine in HIV-1-Infected Subjects Receiving Potent Antiretroviral Therapy (ART).* **Cara Wilson**, B. Livingston, S. MaWhinney, R. Schooley, J. Forster, M. Anders, N. Blyveis, M. Newman, and C.A. Benson. Poster at 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA.
- 2005 *Functional and phenotypic characterization of CD4+ CD57+ T cells and their association with HIV-1-induced T cell dysfunction.* Brent E. Palmer, Naomi Blyveis, and **Cara C. Wilson**. Keystone Symposia on HIV Pathogenesis, Banff, Alberta Canada.
- 2005 *A Phase I Safety and Immunogenicity Study of the Epimmune HIV-1 CTL Epitope-based DNA Vaccine for Immunotherapy of HIV-1 Infected Individuals Receiving HAART.* B.D. Livingston, C.A. Benson, S. MaWhinney, R. Schooley, J. Forster, M. Anders, N. Blyveis, M. Newman, and ***Cara Wilson**. Oral presentation at AIDS Vaccine 2005 International Conference, Montreal, Canada.

